Get the Stockscreener App
1.25
0.00%
0.00
After Hours:
1.24
-0.01
-0.80%
Cardiol Therapeutics Inc stock is traded at $1.25, with a volume of 115.48K.
It is up +0.00% in the last 24 hours and up +8.70% over the past month.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
See More
Previous Close:
$1.25
Open:
$1.25
24h Volume:
115.48K
Relative Volume:
0.61
Market Cap:
$103.31M
Revenue:
-
Net Income/Loss:
$-21.65M
P/E Ratio:
-3.7639
EPS:
-0.3321
Net Cash Flow:
$-15.84M
1W Performance:
+13.64%
1M Performance:
+8.70%
6M Performance:
-22.84%
1Y Performance:
-51.36%
1-Day Range:
$1.19
$1.28
1-Week Range:
$1.07
$1.31
52-Week Range:
$0.7709
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.25 | 90.91M | 0 | -21.65M | -15.84M | -0.3321 |
|
HLN
Haleon Plc Adr
|
11.35 | 50.14B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
168.63 | 72.38B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.79 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.51B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.45B | 16.54B | -1.64B | 749.00M | -1.45 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
(CRDL) Technical Pivots with Risk Controls (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics Announces AGM Results and New Board Member - TipRanks
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | CRDL Stock News - GuruFocus
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders - Newsfile
Ex-Eli Lilly Chief Medical Officer Strengthens Cardiol Board as Critical Phase III Trial Nears Completion - Stock Titan
Cardiol Therapeutics Reports Q1 2025 Financial Results - TipRanks
Cardiol Therapeutics to Webcast Virtual Annual General Meeting o - GuruFocus
(CRDL) Market Insights and Trading Signals (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics Inc. - Baystreet.ca
Stocks In Play: Cardiol Therapeutics Inc. - Barchart.com
Cardiol Therapeutics to Webcast AGM Amidst Ongoing Clinical Trials - TipRanks
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT - Newsfile
Cardiol Therapeutics Announces Virtual AGM: How Shareholders Can Participate Online May 28 - Stock Titan
Cardiol Therapeutics (OTCMKTS:CRTPF) Stock Price Up 2.8% – Here’s Why - Defense World
(CRDL) Investment Performance Report (CRDL:CA) - news.stocktradersdaily.com
AMD Will Be as ‘Aggressive as Possible’ to Challenge Nvidia - The Globe and Mail
(CRDL) Stock Market Analysis (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics (TSE:CRDL) Stock Price Down 5.2% – Time to Sell? - Defense World
(CRDL) Market Performance Analysis (CRDL:CA) - news.stocktradersdaily.com
(CRDL) Strategic Equity Report (CRDL:CA) - news.stocktradersdaily.com
(CRDL) Advanced Trading Insights (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Given Consensus Rating of “Buy” by Analysts - Defense World
Envestnet Asset Management Inc. Makes New Investment in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Lodgement of CONNEQT Pulse Device with the TGA - Investing News Network
(CRDL) Trading Performance and Risk Management (CRDL:CA) - news.stocktradersdaily.com
(CRDL) Daily Stock Insights (CRDL:CA) - news.stocktradersdaily.com
March Quarterly Activities Report - Investing News Network
March Quarterly Appendix 4C - Investing News Network
Cardiol Therapeutics (TSE:CRDL) Trading Up 6.7% – What’s Next? - Defense World
Profound Medical Corp. - Baystreet.ca
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors | CRDL Stock News - GuruFocus
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Board Amid Phase III Trial Progress - TipRanks
The S&P 500 Is Doing Something That Hasn't Been Seen in Nearly 100 Years. Here Are the 10 Most Important Stocks to Keep an Eye On. - The Globe and Mail
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors - Newsfile
Cardiol Therapeutics nominates ex-Eli Lilly CMO to board - Investing.com
Cardiol Therapeutics announces annual shareholder meeting By Investing.com - Investing.com India
Cardiol Therapeutics announces annual shareholder meeting - Investing.com
Cardiol Therapeutics Schedules Virtual Annual General Meeting for May 2025 - TipRanks
First patient dosed in Phase IIb imaging for Brain Mets - Investing News Network
(CRDL) Strategic Market Analysis (CRDL:CA) - news.stocktradersdaily.com
A Heart Disease Cure For Pericarditis? Phase 3 Trial Advances | David ElsleyCardiol Therapeutics - thedeepdive.ca
Long Term Trading Analysis for (CRDL) (CRDL:CA) - news.stocktradersdaily.com
(CRDL) Risk-Controlled Trading Report (CRDL:CA) - news.stocktradersdaily.com
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In? - Nasdaq
Genocea Biosciences (NASDAQ:GNCA) versus Cardiol Therapeutics (NASDAQ:CRDL) Head-To-Head Review - Defense World
(CRDL) Investment Analysis and Advice (CRDL:CA) - news.stocktradersdaily.com
Roth Capital Has Bearish Forecast for CRDL Q1 Earnings - Defense World
Cardiol Therapeutics (CRDL) Projected to Post Quarterly Earnings on Monday - Defense World
Cardiol Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics (NASDAQ:CRDL) Earns “Buy” Rating from HC Wainwright - Defense World
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
18.36%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):